Updated TB-Profiler: enhanced genotypic antimicrobial resistance prediction and relatedness analysis powered by a database of over 171,000 Mycobacterium tuberculosis genomes
Computational analysis reveals expanded drug resistance profiling across 17 therapies in Mycobacterium tuberculosis, highlighting enhanced global genomic surveillance capabilities.
Key Points
To expand TB-Profiler's analytical capabilities by updating drug resistance mutation libraries, integrating a massive global genomic repository, and implementing tools to determine genomic relatedness for outbreak tracking.
Expanded TB-Profiler (v6.6.5) resistance mutation libraries to cover 17 anti-tuberculosis drugs using World Health Organization interpretation rules and curated loss-of-function mutations.
Integrated a curated global database comprising over 170,000 Mycobacterium tuberculosis genomes from 136 countries representing all major phylogenetic lineages.
Implemented algorithms to calculate and visualize genomic relatedness between isolates and evaluated transmission detection using clinical isolates from Uganda.
Updated resistance profiling to cover 17 anti-TB agents, including newly added delamanid, pretomanid, bedaquiline, clofazimine, cycloserine/terizidone, and para-aminosalicylic acid.
Integrated global allele frequency estimation and isolate-relatedness tools that successfully identified potential local transmission events in Ugandan isolate datasets.
Added multilingual reporting functions to support decentralized clinical decision-making and international public health surveillance.